Lenvatinib Oral Product + Pembrolizumab
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
Trial Timeline
May 28, 2021 → Sep 1, 2026
NCT ID
NCT04869137About Lenvatinib Oral Product + Pembrolizumab
Lenvatinib Oral Product + Pembrolizumab is a phase 2 stage product being developed by Merck for Merkel Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04869137. Target conditions include Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04869137 | Phase 2 | Active |
Competing Products
20 competing products in Merkel Cell Carcinoma